Ropeginterferon alfa-2b 250micrograms/0.5ml solution for injection pre-filled disposable devices
NHS hospitals in England used £20,865,295 of indicative cost of Ropeginterferon alfa-2b 250micrograms/0.5ml solution for injection pre-filled disposable devices in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 86.4% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Ropeginterferon alfa-2b 250micrograms/0.5ml solution for injection pre-filled disposable devices: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Ropeginterferon alfa-2b 250micrograms/0.5ml solution for injection pre-filled disposable devices most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Guy's & St Thomas' Nhs Foundation Trust | £3,582,101 |
| Salford Royal Nhs Foundation Trust | £914,238 |
| Nottingham University Hospitals Trust | £696,817 |
| King's College Hpl Nhs Foundation Trust | £482,960 |
| University Hpls Of Leicester Nhs Trust | £472,267 |
| Western Sussex Hospitals Nhs Found Trust | £452,664 |
| Gloucestershire Hpls Nhs Foundation Trst | £443,753 |
| Portsmouth Hospitals Nhs Trust | £441,971 |
| Harrogate & District Foundation Trust | £438,406 |
| United Lincolnshire Hospitals Nhs Trust | £427,714 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.